Supernus Pharmaceuticals (NASDAQ:SUPN) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Wednesday.
A number of other research analysts have also recently weighed in on SUPN. ValuEngine cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 8th. Piper Jaffray Companies set a $47.00 target price on shares of Supernus Pharmaceuticals and gave the company a “hold” rating in a research note on Monday, July 2nd. Stifel Nicolaus lifted their target price on shares of Supernus Pharmaceuticals from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, May 25th. Jefferies Financial Group lifted their target price on shares of Supernus Pharmaceuticals from $55.00 to $58.00 and gave the company a “buy” rating in a research note on Thursday, August 9th. Finally, Cantor Fitzgerald set a $56.00 target price on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $54.09.
SUPN opened at $48.85 on Wednesday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.54 and a current ratio of 2.74. Supernus Pharmaceuticals has a fifty-two week low of $33.30 and a fifty-two week high of $61.25. The firm has a market cap of $2.55 billion, a P/E ratio of 38.77 and a beta of 0.83.
In other Supernus Pharmaceuticals news, VP Stefan K.F. Schwabe sold 60,000 shares of the business’s stock in a transaction on Monday, June 18th. The shares were sold at an average price of $54.39, for a total value of $3,263,400.00. Following the sale, the vice president now owns 21,967 shares in the company, valued at approximately $1,194,785.13. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Gregory S. Patrick sold 35,000 shares of the business’s stock in a transaction on Monday, July 2nd. The stock was sold at an average price of $56.63, for a total transaction of $1,982,050.00. Following the completion of the sale, the chief financial officer now owns 75,975 shares in the company, valued at approximately $4,302,464.25. The disclosure for this sale can be found here. In the last quarter, insiders sold 110,000 shares of company stock worth $6,144,826. Corporate insiders own 6.20% of the company’s stock.
Hedge funds have recently made changes to their positions in the business. Creative Planning lifted its stake in Supernus Pharmaceuticals by 27.1% in the 2nd quarter. Creative Planning now owns 20,719 shares of the specialty pharmaceutical company’s stock worth $1,240,000 after purchasing an additional 4,415 shares in the last quarter. Shaker Investments LLC OH raised its position in shares of Supernus Pharmaceuticals by 16.4% during the 2nd quarter. Shaker Investments LLC OH now owns 49,642 shares of the specialty pharmaceutical company’s stock valued at $2,971,000 after buying an additional 7,002 shares in the last quarter. Reliance Trust Co. of Delaware purchased a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter valued at about $243,000. Cynosure Advisors LLC raised its position in shares of Supernus Pharmaceuticals by 55.0% during the 2nd quarter. Cynosure Advisors LLC now owns 8,260 shares of the specialty pharmaceutical company’s stock valued at $494,000 after buying an additional 2,930 shares in the last quarter. Finally, SevenBridge Financial Group LLC purchased a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter valued at about $113,000. Institutional investors and hedge funds own 97.42% of the company’s stock.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.
Further Reading: Asset Allocation, Balancing Your Investments
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.